Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 16;6(15):4450–4460. doi: 10.1182/bloodadvances.2022006960

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 The American Society of Hematology.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Effect of Iptacopan on LDH and Hb levels. (A) Change in LDH levels over time for iptacopan 25/100 mg and 50/200 mg cohorts (pharmacodynamic analysis set). (B) Change in Hb levels over time for iptacopan 25/100 mg and 50/200 mg cohorts (pharmacodynamic analysis set). Note: 1 patient in cohort 2 (patient 10) was excluded from the Hb analysis due to a protocol deviation, whereby an RBC transfusion was given between screening and baseline, raising the Hb level to above the protocol-defined upper limit of 105 g/L at baseline. bid, twice daily; BL, baseline; LLN, lower limit of normal.

Effect of Iptacopan on LDH and Hb levels. (A) Change in LDH levels over time for iptacopan 25/100 mg and 50/200 mg cohorts (pharmacodynamic analysis set). (B) Change in Hb levels over time for iptacopan 25/100 mg and 50/200 mg cohorts (pharmacodynamic analysis set). Note: 1 patient in cohort 2 (patient 10) was excluded from the Hb analysis due to a protocol deviation, whereby an RBC transfusion was given between screening and baseline, raising the Hb level to above the protocol-defined upper limit of 105 g/L at baseline. bid, twice daily; BL, baseline; LLN, lower limit of normal.